Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Glycoconj J. 2014 Oct;31(0):509–521. doi: 10.1007/s10719-014-9548-4

Table 1.

Patient Data

A. Enzymology assay patient data
Specimen Sample ID Cancer Histology Pathology Stage
Breast 1 Breast Infiltrating duct carcinoma IIB
2 Breast Infiltrating duct mixed with other types of carcinoma IIB
3 Breast Comedocarcinomanon-infiltrating 0
4 Breast Infiltrating duct and lobular carcinoma IIB
5 Breast Infiltrating duct carcinoma IIA
6 Breast Infiltrating duct carcinoma IIIB

Colon 1 Colorectal Adenocarcinoma IIA
2 Colorectal Adenocarcinoma IV
3 Colorectal Adenocarcinoma IIIC
4 Colon Adenocarcinoma -
5 Colon Serous surface papillary carcinoma -
6 Colon Adenocarcinoma IIA

Prostate 1 Prostate Adenocarcinoma III
2 Prostate Adenocarcinoma II
3 Prostate Adenocarcinoma III
4 Prostate Adenocarcinoma -
5 Prostate Adenocarcinoma II
B. Breast tumor microarray patient data
Parameter vs # of patients
Diagnosis Age # Tumor size # Pathological stage # Node stage #
25–35 5 T1 67 IIA 47 N0 31
35–45 22 T2 13 IIB 45 N1 74
45–55 27 T3 15 IIIA 8 N2 3
55–65 33 T4 20 IIIB 12 N3 7
65–75 15 IIIC 1
75–95 13 IV 2

Metastatic # ER # PR # HER-2 #
M0 113 Positive 101 Positive 77 Negative 90
M1 2 Negative 13 Negative 37 Weak 13
Not determined 1 Not determined 1 Strong 11
HHS Vulnerability Disclosure